Evidence map›Paper›PMID 36135067›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report.

Huanlan Sa, Yinghui Xu, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Kewei Ma

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Huanlan SaCancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Yinghui XuCancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Xiaobo MaPathology Department, The First Hospital of Jilin University, Changchun 130021, China.
Xu WangCancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Chao SunCancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Shi QiuCancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Ye GuoCancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Zhiguang YangDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun 130021, China.
Yunpeng LiuDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun 130021, China.
Kewei MaCancer Center, The First Hospital of Jilin University, Changchun 130021, China.ORCID 0000-0003-2987-576X
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoma ex pleomorphic adenoma (Ca ex PA) is a rare malignant tumor that arises from a primary or recurrent benign pleomorphic adenoma (PA). Ca ex PA has an aggressive behavior and poor prognosis. To date, there are no standardized therapeutic methods. Herein, we reported a case of a 57-year-old Chinese female with Ca ex PA of the submandibular gland. After surgery, cervical lymph nodes recurred, and multiple distant metastases were detected. During the treatment, she received multiple chemotherapies and radiotherapy but suffered from multidrug resistance and repeated disease progression. Hence, PD-1 inhibitor (sintilimab), in combination with anlotinib, was administered, which resulted in better control of pulmonary metastases compared to the other treatment regimens. This provided an alternative treatment option for Ca ex PA of the submandibular gland patients with failed multiple therapies.

Indexed as

AdenocarcinomaAdenoma, PleomorphicFemaleHumansImmune Checkpoint InhibitorsImmunotherapyMiddle AgedNeoplasm Recurrence, LocalSubmandibular GlandImmune Checkpoint Inhibitorsantiangiogenic therapycarcinoma ex pleomorphic adenomaimmunotherapysubmandibular gland

Identifiers

PMID36135067
PMCPMC9497983
OpenAlexW4294151582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.